Congenital sideroblastic anemia successfully treated by allogeneic bone marrow transplantation.

Abstract

Allogeneic bone marrow transplantation (BMT) was carried out on a 34-month-old boy with congenital sideroblastic anemia. The patient had been red blood cell transfusion dependent since the age of 7 weeks. He did not respond to therapy with pyridoxine and developed secondary progressive hemosiderosis. The preparatory regimen consisted of busulfan (3.5 mg/kg for 4 days) and cyclophosphamide (50 mg/kg for 4 days). Full engraftment of donor bone marrow was achieved and effective hemopoiesis is still maintained 3 years after BMT.

• Authors: C Urban, B Binder, C Hauer, G Lanzer
• Journal: Bone marrow transplantation (Bone Marrow Transplant) Vol. 10 Issue 4 Pg. 373-5 (Oct 1992) ISSN: 0268-3369 [Print] England
• PMID: 1422494 (Publication Type: Case Reports, Journal Article)

Chemical References

• Cyclophosphamide
• Busulfan

Topics

• Anemia, Sideroblastic (congenital, drug therapy, surgery)
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
• Bone Marrow Transplantation
• Busulfan (administration & dosage)
• Child, Preschool
• Combined Modality Therapy
• Cyclophosphamide (administration & dosage)
• Humans
• Male
• Transplantation, Homologous